| Year |
Title |
Altmetric |
| 2020
|
Dysregulation of de novo nucleotide biosynthetic pathway enzymes in cancer and targeting opportunities.
Cancer Letters.
470:134-140.
2020
|
|
| 2019
|
Pan-cancer molecular subtypes revealed by mass-spectrometry-based proteomic characterization of more than 500 human cancers.
Nature Communications.
10.
2019
|
|
| 2019
|
Expression and Role of Methylenetetrahydrofolate Dehydrogenase 1 Like (MTHFD1L) in Bladder Cancer.
Translational Oncology.
12:1416-1424.
2019
|
|
| 2019
|
MTHFD1L, A Folate Cycle Enzyme, Is Involved in Progression of Colorectal Cancer.
Translational Oncology.
12:1461-1467.
2019
|
|
| 2019
|
Pseudogene Associated Recurrent Gene Fusion in Prostate Cancer.
Neoplasia : An International Journal for Oncology Research.
21:989-1002.
2019
|
|
| 2019
|
Characterization of glycine-N-acyltransferase like 1 (GLYATL1) in prostate cancer.
Prostate.
Epub ahead of print.
2019
|
|
| 2019
|
Large-scale profiling of serum metabolites in African American and European American patients with bladder cancer reveals metabolic pathways associated with patient survival.
Cancer.
125:921-932.
2019
|
|
| 2019
|
Inhibition of Hedgehog signaling reprograms the dysfunctional immune microenvironment in breast cancer.
OncoImmunology.
8.
2019
|
|
| 2019
|
Genome-wide DNA methylation encodes cardiac transcriptional reprogramming in human ischemic heart failure.
Laboratory Investigation.
99:371-386.
2019
|
|
| 2019
|
Molecular correlates of metastasis by systematic pan-cancer analysis across the cancer genome atlas.
Cell Growth and Differentiation.
17:476-487.
2019
|
|
| 2019
|
The combined survival effect of codon 72 polymorphisms and p53 somatic mutations in breast cancer depends on race and molecular subtype.
PLoS ONE.
14.
2019
|
|
| 2019
|
Characterization of glycine-N-acyltransferase like 1 (GLYATL1) in prostate cancer.
Prostate.
79:1629-1639.
2019
|
|
| 2019
|
Ferritin light chain confers protection against sepsis-induced inflammation and organ injury.
Frontiers in Immunology.
10.
2019
|
|
| 2019
|
Integrative epigenetic and gene expression analysis of renal tumor progression to metastasis.
Cell Growth and Differentiation.
17:84-96.
2019
|
|
| 2018
|
Wnt receptor Frizzled 8 is a target of ERG in prostate cancer.
Prostate.
78:1311-1320.
2018
|
|
| 2018
|
A Role for De Novo Purine Metabolic Enzyme PAICS in Bladder Cancer Progression.
Neoplasia : An International Journal for Oncology Research.
20:894-904.
2018
|
|
| 2018
|
Gene Expression Profiling of Advanced Penile Squamous Cell Carcinoma Receiving Cisplatin-based Chemotherapy Improves Prognostication and Identifies Potential Therapeutic Targets.
European urology focus.
4:733-736.
2018
|
|
| 2018
|
miR-34a regulates expression of the stathmin-1 oncoprotein and prostate cancer progression.
Cell Growth and Differentiation.
16:1125-1137.
2018
|
|
| 2018
|
214 High fat diet accelerates UVB-induced development of basal cell and squamous cell carcinoma in Ptch+/-/SKH-1 mice.
Journal of Investigative Dermatology.
138:S36-S36.
2018
|
|
| 2018
|
Histone methyltransferase ezh2: A therapeutic target for ovarian cancer.
Molecular Cancer Therapeutics.
17:591-602.
2018
|
|
| 2018
|
Chemotherapy induces secretion of exosomes loaded with heparanase that degrades extracellular matrix and impacts tumor and host cell behavior.
Collagen and related research.
65:104-118.
2018
|
|
| 2017
|
Prostate Cancer: An Update on Molecular Pathology with Clinical Implications.
European Urology Supplements.
16:253-271.
2017
|
|
| 2017
|
Prostate cancer imaging and biomarkers guiding safe selection of active surveillance.
Frontiers in Oncology.
7.
2017
|
|
| 2017
|
UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses.
Neoplasia : An International Journal for Oncology Research.
19:649-658.
2017
|
|
| 2017
|
Development of Peptidomimetic Inhibitors of the ERG Gene Fusion Product in Prostate Cancer.
Cancer Cell.
31:532-548.e7.
2017
|
|
| 2017
|
Erratum: Development of Peptidomimetic Inhibitors of the ERG Gene Fusion Product in Prostate Cancer (Cancer Cell (2017) 31(4) (532–548.e7)(S1535610817300600)(10.1016/j.ccell.2017.02.017)).
Cancer Cell.
31:844-847.
2017
|
|
| 2017
|
Amplified centrosomes and mitotic index display poor concordance between patient tumors and cultured cancer cells.
Scientific Reports.
7.
2017
|
|
| 2017
|
Loss of RUNX3 expression is an independent adverse prognostic factor in diffuse large B-cell lymphoma.
Leukemia & Lymphoma.
58:179-184.
2017
|
|
| 2017
|
Expression and Role of PAICS, a De Novo Purine Biosynthetic Gene in Prostate Cancer.
Prostate.
77:10-21.
2017
|
|
| 2016
|
MicroRNA-101 regulated transcriptional modulator SUB1 plays a role in prostate cancer.
Oncogene.
35:6330-6340.
2016
|
|
| 2016
|
Genomic and Epigenomic Alterations in Cancer.
American Journal of Pathology.
186:1724-1735.
2016
|
|
| 2016
|
Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer.
Nature Medicine.
22:298-305.
2016
|
|
| 2016
|
Erratum: TRIP13 promotes error-prone nonhomologous end joining and induces chemoresistance in head and neck cancer (Nature Communications (2014) 5 (4527) DOI: 10.1038/ncomms5527).
Nature Communications.
7.
2016
|
|
| 2016
|
Association between Hepatitis C Virus Infection, p53 Phenotypes, and Gene Variants of Adenomatous Polyposis Coli in Hepatocellular Carcinomas..
J Dig Dis Hepatol.
2016.
2016
|
|
| 2016
|
Cancer mediates effector T cell dysfunction by targeting microRNAs and EZH2 via glycolysis restriction.
Nature Immunology.
17:95-103.
2016
|
|
| 2015
|
Amplified centrosomes may underlie aggressive disease course in pancreatic ductal adenocarcinoma.
Cell Cycle.
14:2798-2809.
2015
|
|
| 2015
|
Cancer: The kinase activity of the Ser/Thr kinase BUB1 promotes TGF-β signaling.
Science Signaling.
8.
2015
|
|
| 2015
|
Role and regulation of coordinately expressed de novo purine biosynthetic enzymes PPAT and PAICS in lung cancer.
Oncotarget.
6:23445-23461.
2015
|
|
| 2014
|
TRIP13 promotes error-prone nonhomologous end joining and induces chemoresistance in head and neck cancer.
Nature Communications.
5.
2014
|
|
| 2014
|
The miR-124-prolyl hydroxylase P4HA1-MMP1 axis plays a critical role in prostate cancer progression.
Oncotarget.
5:6654-6669.
2014
|
|
| 2013
|
Targeting the link between late pregnancy and breast cancer.
eLife.
2013.
2013
|
|
| 2013
|
Prostate cancer genomics: Progress and promise.
European Urology.
64:577-578.
2013
|
|
| 2013
|
Erratum: Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression (Nature (2009) 457 (910-914) DOI: 10.1038/nature07762).
Nature.
499:504.
2013
|
|
| 2013
|
Erratum to Mechanistic rationale for inhibition of poly(ADP-Ribose) polymerase in ETS gene fusion-positive prostate cancer [Cancer Cell, 19 (2011) 664-678].
Cancer Cell.
23:557.
2013
|
|
| 2013
|
Characterization of the EZH2-MMSET Histone Methyltransferase Regulatory Axis in Cancer.
Molecular Cell.
49:80-93.
2013
|
|
| 2012
|
The enzymatic activity of apoptosis-inducing factor supports energy metabolism benefiting the growth and invasiveness of advanced prostate cancer cells..
Journal of Biological Chemistry.
287:43862-43875.
2012
|
|
| 2012
|
Role of dutasteride in pre-clinical ETS fusion-positive prostate cancer models.
Prostate.
72:1542-1549.
2012
|
|
| 2012
|
Inhibition of histone methylation arrests ongoing graft-versus-host disease in mice by selectively inducing apoptosis of alloreactive effector T cells.
Blood.
119:1274-1282.
2012
|
|
| 2012
|
Role of transcriptional corepressor CtBP1 in prostate cancer progression.
Neoplasia : An International Journal for Oncology Research.
14:905-914.
2012
|
|
| 2011
|
The tumor suppressor gene rap1GAP is silenced by miR-101-mediated EZH2 overexpression in invasive squamous cell carcinoma.
Oncogene.
30:4339-4349.
2011
|
|
| 2011
|
Coordinated Regulation of Polycomb Group Complexes through microRNAs in Cancer.
Cancer Cell.
20:187-199.
2011
|
|
| 2011
|
TMPRSS2-ERG-mediated feed-forward regulation of wild-type ERG in human prostate cancers.
Cancer Research.
71:5387-5392.
2011
|
|
| 2011
|
Targeting of microRNA-142-3p in dendritic cells regulates endotoxin-induced mortality.
Blood.
117:6172-6183.
2011
|
|
| 2011
|
Characterization of KRAS rearrangements in metastatic prostate cancer.
Cancer Discovery.
1:35-43.
2011
|
|
| 2011
|
Mechanistic Rationale for Inhibition of Poly(ADP-Ribose) Polymerase in ETS Gene Fusion-Positive Prostate Cancer.
Cancer Cell.
19:664-678.
2011
|
|
| 2011
|
Therapeutic targeting of SPINK1-positive prostate cancer.
Science Translational Medicine.
3.
2011
|
|
| 2010
|
The neuronal repellent SLIT2 is a target for repression by EZH2 in prostate cancer.
Oncogene.
29:5370-5380.
2010
|
|
| 2010
|
Letter to the editor.
European Urology.
58.
2010
|
|
| 2010
|
Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma.
Nature Medicine.
16:793-798.
2010
|
|
| 2010
|
An Integrated Network of Androgen Receptor, Polycomb, and TMPRSS2-ERG Gene Fusions in Prostate Cancer Progression.
Cancer Cell.
17:443-454.
2010
|
|
| 2010
|
Antibody-based detection of ERG rearrangement-positive prostate cancer.
Neoplasia : An International Journal for Oncology Research.
12:590-598.
2010
|
|
| 2010
|
Chlorpromazine induced cataract in a young patient with schizophrenia..
Indian Journal of Psychological Medicine.
32:69-70.
2010
|
|
| 2009
|
Induced chromosomal proximity and gene fusions in prostate cancer.
Science.
326:1230.
2009
|
|
| 2009
|
An integrative approach to reveal driver gene fusions from paired-end sequencing data in cancer.
Nature Biotechnology.
27:1005-1011.
2009
|
|
| 2009
|
Proteomic interrogation of androgen action in prostate cancer cells reveals roles of aminoacyl tRNA synthetases.
PLoS ONE.
4.
2009
|
|
| 2009
|
AGTR1 overexpression defines a subset of breast cancer and confers sensitivity to losartan, an AGTR1 antagonist.
Proceedings of the National Academy of Sciences.
106:10284-10289.
2009
|
|
| 2009
|
Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression.
Nature.
457:910-914.
2009
|
|
| 2009
|
Tomlins et al. reply.
Nature.
457.
2009
|
|
| 2009
|
RHAMM (CD168) is overexpressed at the protein level and may constitute an immunogenic antigen in advanced prostate cancer disease.
Neoplasia : An International Journal for Oncology Research.
11:956-963.
2009
|
|
| 2008
|
Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer.
Science.
322:1695-1699.
2008
|
|
| 2008
|
Repression of E-cadherin by the polycomb group protein EZH2 in cancer.
Oncogene.
27:7274-7284.
2008
|
|
| 2008
|
A fluorescence in situ hybridization screen for E26 transformation-specific aberrations: Identification of DDX5-ETV4 fusion protein in prostate cancer.
Cancer Research.
68:7629-7637.
2008
|
|
| 2008
|
The Role of SPINK1 in ETS Rearrangement-Negative Prostate Cancers.
Cancer Cell.
13:519-528.
2008
|
|
| 2008
|
Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer.
Cancer Research.
68:73-80.
2008
|
|
| 2008
|
Golgi protein GOLM1 is a tissue and urine biomarker of prostate cancer.
Neoplasia : An International Journal for Oncology Research.
10:1285-1294.
2008
|
|
| 2008
|
Inhibition of CCN6 (Wnt-1-induced signaling protein 3) down-regulates E-cadherin in the breast epithelium through induction of snail and ZEB1.
American Journal of Pathology.
172:893-904.
2008
|
|
| 2008
|
Role of the TMPRSS2-ERG gene fusion in prostate cancer.
Neoplasia : An International Journal for Oncology Research.
10:177-188.
2008
|
|
| 2007
|
Tumor cell-selective regulation of NOXA by c-MYC in response to proteasome inhibition.
Proceedings of the National Academy of Sciences.
104:19488-19493.
2007
|
|
| 2007
|
A polycomb repression signature in metastatic prostate cancer predicts cancer outcome.
Cancer Research.
67:10657-10663.
2007
|
|
| 2007
|
Integrative Genomics Analysis Reveals Silencing of β-Adrenergic Signaling by Polycomb in Prostate Cancer.
Cancer Cell.
12:419-431.
2007
|
|
| 2007
|
Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer.
Nature.
448:595-599.
2007
|
|
| 2007
|
Role of epidermal growth factor receptor degradation in gemcitabine-mediated cytotoxicity.
Oncogene.
26:3431-3439.
2007
|
|
| 2007
|
Effect of epidermal growth factor receptor inhibitor class in the treatment of head and neck cancer with concurrent radiochemotherapy in vivo.
Clinical Cancer Research.
13:2512-2518.
2007
|
|
| 2007
|
Autoantibody profiles reveal ubiquilin 1 as a humoral immune response target in lung adenocarcinoma.
Cancer Research.
67:3461-3467.
2007
|
|
| 2007
|
Molecular concepts analysis links tumors, pathways, mechanisms, and drugs.
Neoplasia : An International Journal for Oncology Research.
9:443-454.
2007
|
|
| 2007
|
Oncomine 3.0: Genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles.
Neoplasia : An International Journal for Oncology Research.
9:166-180.
2007
|
|
| 2006
|
Ataxia telangiectasia mutated down-regulates phospho-extracellular signal-regulated kinase 1/2 via activation of MKP-1 in response to radiation.
Cancer Research.
66:11554-11559.
2006
|
|
| 2006
|
Selection and cloning of poly(rC)-binding protein 2 and Raf kinase inhibitor protein RNA activators of 2′,5′-oligoadenylate synthetase from prostate cancer cells.
Nucleic Acids Research.
34:6684-6695.
2006
|
|
| 2006
|
Differential proteomic alterations between localised and metastatic prostate cancer.
British Journal of Cancer.
95:425-430.
2006
|
|
| 2006
|
A systems approach to model metastatic progression.
Cancer Research.
66:5537-5539.
2006
|
|
| 2006
|
Enhancing the antitumor activity of ErbB blockade with histone deacetylase (HDAC) inhibition.
International Journal of Cancer.
118:1041-1050.
2006
|
|
| 2006
|
Nod1 acts as an intracellular receptor to stimulate chemokine production and neutrophil recruitment in vivo.
Journal of Experimental Medicine.
203:203-213.
2006
|
|
| 2006
|
ADAM15 disintegrin is associated with aggressive prostate and breast cancer disease.
Neoplasia : An International Journal for Oncology Research.
8:319-329.
2006
|
|
| 2006
|
Defining aggressive prostate cancer using a 12-gene model.
Neoplasia : An International Journal for Oncology Research.
8:59-68.
2006
|
|
| 2005
|
Identification of GATA3 as a breast cancer prognostic marker by global gene expression meta-analysis.
Cancer Research.
65:11259-11264.
2005
|
|
| 2005
|
Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression.
Cancer Cell.
8:393-406.
2005
|
|
| 2005
|
Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.
Science.
310:644-648.
2005
|
|
| 2005
|
Autoantibody signatures in prostate cancer.
New England Journal of Medicine.
353:1224-1235.
2005
|
|
| 2005
|
Probabilistic model of the human protein-protein interaction network.
Nature Biotechnology.
23:951-959.
2005
|
|
| 2005
|
The unfolded protein response modulates toxicity of the expanded glutamine androgen receptor.
Journal of Biological Chemistry.
280:21264-21271.
2005
|
|
| 2005
|
α-methylacyl-CoA racemase protein expression is associated with the degree of differentiation in breast cancer using quantitative image analysis.
Cancer Epidemiology, Biomarkers and Prevention.
14:1418-1423.
2005
|
|
| 2005
|
Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva).
Cancer Research.
65:3328-3335.
2005
|
|
| 2005
|
The polycomb group protein EZH2 impairs DNA repair in breast epithelial cells.
Neoplasia : An International Journal for Oncology Research.
7:1011-1019.
2005
|
|
| 2004
|
Androgen-independent prostate cancer is a heterogeneous group of diseases: Lessons from a rapid autopsy program.
Cancer Research.
64:9209-9216.
2004
|
|
| 2004
|
JAGGED1 expression is associated with prostate cancer metastasis and recurrence.
Cancer Research.
64:6854-6857.
2004
|
|
| 2004
|
Natural antibodies sustain differentiation and maturation of human dendritic cells.
Proceedings of the National Academy of Sciences.
101:14210-14215.
2004
|
|
| 2004
|
Overexpression, amplification, and androgen regulation of TPD52 in prostate cancer. Rubin, MA, Varambally S, Beroukhim R, Tomlins SA, Rhodes DR, Paris PL, Hofer, MD, Storz-Schweizer M, Kuefer R, Fletcher JA, Hsi BL, Byrne JA, Pienta KJ, Collins C, Sellers WR, Chinnaiyan AM, Department of Pathology, Brigham and Women's Hospital, Boston, MA..
Urologic Oncology: Seminars and Original Investigations.
22:436-437.
2004
|
|
| 2004
|
Overexpression, amplification, and androgen regulation of TPD52 in prostate cancer.
Cancer Research.
64:3814-3822.
2004
|
|
| 2004
|
Natural human polyreactive IgM induce apoptosis of lymphoid cell lines and human peripheral blood mononuclear cells.
International Immunology.
16:517-524.
2004
|
|
| 2004
|
The Role of Metastasis-Associated Protein 1 in Prostate Cancer Progression.
Cancer Research.
64:825-829.
2004
|
|
| 2004
|
C5a-Induced Gene Expression in Human Umbilical Vein Endothelial Cells.
American Journal of Pathology.
164:849-859.
2004
|
|
| 2003
|
EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells.
Proceedings of the National Academy of Sciences.
100:11606-11611.
2003
|
|
| 2002
|
Changes in differential gene expression because of warm ischemia time of radical prostatectomy specimens.
American Journal of Pathology.
161:1743-1748.
2002
|
|
| 2002
|
The polycomb group protein EZH2 is involved in progression of prostate cancer.
Nature.
419:624-629.
2002
|
|
| 2002
|
Autoantibodies to heat shock protein 90 in the human natural antibody repertoire.
International Immunology.
14:453-461.
2002
|
|
| 2002
|
α-methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer.
Journal of the American Medical Association.
287:1662-1670.
2002
|
|
| 2002
|
Molecular cross-talk between the TRAIL and interferon signaling pathways.
Journal of Biological Chemistry.
277:575-585.
2002
|
|
| 2002
|
α-Methylacyl-CoA racemase: Expression levels of this novel cancer biomarker depend on tumor differentiation.
American Journal of Pathology.
161:841-848.
2002
|
|
| 2001
|
Profiling of cancer cells using protein microarrays: Discovery of novel radiation-regulated proteins.
Cancer Research.
61:7585-7593.
2001
|
|
| 2001
|
Delineation of prognostic biomarkers in prostate cancer.
Nature.
412:822-826.
2001
|
|
| 2001
|
Variable Sensitivity of Lymphoblastoid Cells to Apoptosis Induced by Viscum album Qu FrF, a Therapeutic Preparation of Mistletoe Lectin.
Chemotherapy.
47:366-376.
2001
|
|
| 2000
|
Natural Antibodies to Factor VIII.
Seminars in Thrombosis and Hemostasis.
Volume 26:157-166.
2000
|
|
| 1999
|
Catalytic activity of antibodies against factor VIII in patients with hemophilia A.
Nature Medicine.
5:1044-1047.
1999
|
|
| 1998
|
Refolding of native and recombinant chicken riboflavin carrier (or binding) protein : evidence for the formation of non-native intermediates during the generation of active protein.
European Journal of Biochemistry.
258:411-418.
1998
|
|
| 1998
|
Identification and characterization of receptors for riboflavin carrier protein in the chicken oocyte.
BBA - Proteins and Proteomics.
1382:230-242.
1998
|
|
| 1996
|
Hyperexpression of Chicken Riboflavin Carrier Protein: Antibodies to the Recombinant Protein Curtail Pregnancy in Rodents.
Protein Expression and Purification.
7:147-154.
1996
|
|
